In conclusion, for pretreated advanced NSCLC patients with no EGFR mutations or ALK translocations, using the PD-L1 test to guide second-line nivolumab treatment might not be considered cost-effective from the perspective of the Chinese healthcare system. Here, CD274 is linked to non-small cell lung carcinoma.